Cardlytics (NASDAQ:CDLX) Shares Gap Up to $37.42

Cardlytics Inc (NASDAQ:CDLX)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $39.37, but opened at $37.42. Cardlytics shares last traded at $38.19, with a volume of 340,983 shares changing hands.

CDLX has been the topic of a number of analyst reports. William Blair initiated coverage on Cardlytics in a report on Monday, July 1st. They issued an “outperform” rating on the stock. SunTrust Banks lifted their price target on Cardlytics from $25.00 to $35.00 and gave the company a “buy” rating in a report on Friday, August 9th. Zacks Investment Research downgraded Cardlytics from a “buy” rating to a “hold” rating in a report on Tuesday, July 23rd. JPMorgan Chase & Co. set a $43.00 price target on Cardlytics and gave the company a “buy” rating in a report on Friday, August 9th. Finally, Raymond James lifted their price target on Cardlytics from $24.00 to $40.00 and gave the company an “outperform” rating in a report on Friday, August 9th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $33.29.

The company has a 50 day moving average of $32.99 and a two-hundred day moving average of $23.66. The company has a debt-to-equity ratio of 0.79, a quick ratio of 2.01 and a current ratio of 2.01. The stock has a market capitalization of $844.57 million, a PE ratio of -17.51 and a beta of 1.55.



Cardlytics (NASDAQ:CDLX) last announced its earnings results on Thursday, August 8th. The company reported ($0.12) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.35) by $0.23. Cardlytics had a negative return on equity of 66.01% and a negative net margin of 19.60%. The firm had revenue of $48.73 million for the quarter, compared to the consensus estimate of $43.77 million. During the same period in the previous year, the business earned ($0.21) EPS. The firm’s revenue for the quarter was up 37.0% on a year-over-year basis. As a group, research analysts predict that Cardlytics Inc will post -1.08 EPS for the current fiscal year.

In related news, CEO Scott D. Grimes sold 6,000 shares of the business’s stock in a transaction on Tuesday, July 2nd. The stock was sold at an average price of $30.00, for a total transaction of $180,000.00. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, CEO Scott D. Grimes sold 4,000 shares of the business’s stock in a transaction on Tuesday, June 25th. The stock was sold at an average price of $23.76, for a total value of $95,040.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 2,354,392 shares of company stock worth $72,349,708. 21.90% of the stock is owned by company insiders.

A number of hedge funds have recently made changes to their positions in the stock. Gamco Investors INC. ET AL grew its stake in Cardlytics by 2.6% during the 2nd quarter. Gamco Investors INC. ET AL now owns 15,850 shares of the company’s stock worth $412,000 after buying an additional 400 shares during the last quarter. Bank of Montreal Can grew its stake in Cardlytics by 16,371.4% during the 2nd quarter. Bank of Montreal Can now owns 1,153 shares of the company’s stock valued at $30,000 after purchasing an additional 1,146 shares during the last quarter. SG Americas Securities LLC grew its stake in Cardlytics by 2.3% during the 1st quarter. SG Americas Securities LLC now owns 61,277 shares of the company’s stock valued at $1,014,000 after purchasing an additional 1,402 shares during the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in Cardlytics during the 2nd quarter valued at about $60,000. Finally, CIBC Private Wealth Group LLC grew its stake in Cardlytics by 6.7% during the 1st quarter. CIBC Private Wealth Group LLC now owns 37,745 shares of the company’s stock valued at $624,000 after purchasing an additional 2,375 shares during the last quarter. Hedge funds and other institutional investors own 85.01% of the company’s stock.

Cardlytics Company Profile (NASDAQ:CDLX)

Cardlytics, Inc operates a purchase intelligence platform in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a proprietary native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels.

Recommended Story: Call Option

Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.